Booster meningococcal vaccine for children who had earlier dose
Part of Brain & nervous system, Infections clinical trials.
This study tests a booster shot of a meningococcal vaccine (which protects against four types of meningitis) in children who already received the same type of vaccine years ago. The goal is to see if a booster can refresh and strengthen protection against these serious infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You previously took part in an earlier CanSino meningococcal vaccine trial (protocol CTP-MCVF-002) as a child aged 4–6 years.
- It has been at least 3 years since you finished the vaccination series in that earlier trial.
- You have not received any other meningococcal vaccine since completing the earlier trial.
- You do not have a low platelet count, a bleeding or clotting disorder, or current use of blood-thinning medication.
- You have not had meningitis since the earlier trial ended.
- You are able to provide identification and sign an informed consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new vaccine safely protects infants aged 6 to 11 months against four types of meningococcal bacteria that can cause serious infections like meningitis and blood infections. It is designed for healthy babies who have not yet received any meningococcal vaccine.
This study tests a vaccine that protects against four common types of meningitis (groups A, C, Y, and W135) in toddlers aged 12–23 months. It helps researchers see if the vaccine is safe and works well for young children.
This trial tests a vaccine that protects against four types of meningococcal bacteria (groups A, C, W, and Y) in healthy babies aged 3 to 5 months. The vaccine is given to help prevent meningitis and other serious infections.
This trial tests a new combination vaccine that protects against whooping cough, Haemophilus influenzae type b (a cause of meningitis and pneumonia), and several types of meningococcal disease (a cause of meningitis and bloodstream infections). It may help reduce the number of shots needed for children.
This study tests a booster dose of a 13-valent pneumonia vaccine (which protects against 13 types of pneumococcal bacteria) in children who already received the full series about 4 years ago in an earlier study. It aims to see if a booster helps maintain protection.
This study tests a new vaccine that may protect against several types of meningococcal bacteria, which can cause serious infections like meningitis. It is given as a single shot to healthy people aged 2 to 59 years.
Hear when a new Epidemic Meningitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.